New target profiling for gastrointestinal disorders: Where are we going?

Current Opinion in Pharmacology

Volumn 12, Issue 6, 2012, Pages 629-631

  Sanger, Gareth J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; CAMICINAL; CANNABINOID RECEPTOR; G PROTEIN COUPLED RECEPTOR; GUANYLATE CYCLASE; GUANYLATE CYCLASE C; LINACLOTIDE; LUBIPROSTONE; MOTILIN; PROBIOTIC AGENT; PROTEIN GPR39; PROTEIN GPR55; PRUCALOPRIDE; PURINERGIC P2X RECEPTOR; PURINERGIC P2Y RECEPTOR; ULIMORELIN; UNCLASSIFIED DRUG;

BIFIDOBACTERIUM LONGUM INFANTIS; CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME; DRUG MECHANISM; DRUG TARGETING; GASTRIC DYSMOTILITY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HUMAN; IRRITABLE COLON; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW;

EID: 84870532578     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.10.006     Document Type: Editorial

References (4)

1. G.J. Sanger, and D. Alpers Development of drugs for gastrointestinal motor disorders: translating science to clinical need Neurogastroenterol Motil 20 2008 177 184
2. E. Dolgin Drug pipeline is flush with new options for chronic constipation Nat Med 18 2012 1309
3. L.R. Rivera, D.P. Poole, M. Thacker, and J.B. Furness The involvement of nitric oxide synthase neurons in enteric neuropathies Neurogastroenterol Motil 23 2011 980 988
4. O.-G. Berge Predictive validity of behavioural animal models for chronic pain Br J Pharmacol 164 2011 1195 1206